Express Scripts eyeing M&A in anticipation of Anthem loss
April 26, 2017
Practice Management | Saint Louis, MO
Express Scripts (NASDAQ: ESRX) has reiterated that making strategic acquisitions remains one of its "priorities for deploying capital" as the US pharmacy benefit manager faces a messy separation from health insurer Anthem (NYSE: ANTM), which filed a $15 billion lawsuit last May accusing Express Scripts of overcharging for prescription drugs. On Monday, Express Scripts announced 1Q net income of $546.3 million. However, business with Anthem, which accounted for roughly a third of its earnings in 2016, will likely end when their contract expires in 2019, according to Reuters.